Regentis Biomaterials Ltd.
RGNT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RGNT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGNT
Regentis Biomaterials Ltd. is a development-stage medical device company focused on its Gelrin hydrogel platform and lead product candidate GelrinC, with no product revenue and a history of operating losses.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Regentis Biomaterials Ltd. is a development-stage medical device company focused on its Gelrin hydrogel platform and lead product candidate GelrinC, with no product revenue and a history of operating losses.
- Regentis is a development-stage medical device company with a limited operating history, focused on its Gelrin hydrogel platform and lead product candidate GelrinC [sec · filed 2026-02-24].
- As of December 31, 2025, the company had cash and cash equivalents of approximately $7.4 million and an accumulated deficit of approximately $55.8 million [sec · filed 2026-02-24].
- The company has not generated any revenue from product sales and expects to continue incurring significant losses until it obtains regulatory approvals to commercialize GelrinC [sec · filed 2026-02-24].
- Regentis raised gross proceeds of $10 million in its initial public offering in December 2025 [sec · filed 2026-02-24].
- The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern [sec · filed 2026-02-24].
What works
- Regentis has a proprietary Gelrin hydrogel platform technology that it is developing for multiple potential applications, with GelrinC as the lead candidate [sec · filed 2026-02-24].
- The company successfully completed an initial public offering in December 2025, raising $10 million in gross proceeds to fund operations [sec · filed 2026-02-24].
What to weigh
- Regentis has a limited operating history, has incurred significant operating losses since inception, and has never generated revenue from product sales [sec · filed 2026-02-24].
- The company expects to continue incurring losses for the foreseeable future and will need to raise substantial additional funding, which may not be available on acceptable terms [sec · filed 2026-02-24].
- Regentis faces intense competition from companies with greater resources and experience in marketing, distributing, and selling products or treatment alternatives [sec · filed 2026-02-24].
- The company's financial statements include an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern [sec · filed 2026-02-24].
From the filings
Quoted directly from source documents.
Regentis has not generated any revenue from product sales and may never be profitable.
“We have not generated any revenue from product sales and may never be profitable.”
SEC filings · February 24, 2026
As of December 31, 2025, cash and cash equivalents were $7.4 million and accumulated deficit was $55.8 million.
“As of December 31, 2025, our cash and cash equivalents were approximately $7.4 million, and as of December 31, 2025, we had an accumulated deficit of approximately $55.8 million, respectively.”
SEC filings · February 24, 2026
The company's financial statements contain a going concern explanatory paragraph.
“Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtainin”
SEC filings · February 24, 2026
Regentis raised $10 million in gross proceeds from its initial public offering in December 2025.
“In December 2025, we raised gross proceeds of $10 million in our initial public offering.”
SEC filings · February 24, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Financial statements include an explanatory paragraph about substantial doubt on ability to continue as a going concern [sec · filed 2026-02-24].
- No revenue and ongoing losses — Company has never generated product revenue and expects continued significant losses until regulatory approval [sec · filed 2026-02-24].
- Need for additional funding — Will require substantial additional capital, which may not be available on acceptable terms or at all [sec · filed 2026-02-24].
- Clinical and regulatory delays — Delays in clinical trials or regulatory review could prevent or delay commercialization of GelrinC [sec · filed 2026-02-24].
What to watch
- Progress and results of clinical trials for GelrinC and the Gelrin hydrogel platform [sec · filed 2026-02-24].
- Ability to secure additional financing to fund operations and development [sec · filed 2026-02-24].
- Regulatory milestones and timing for potential approval of GelrinC in the United States [sec · filed 2026-02-24].
- Cash burn rate and whether existing cash ($7.4M as of Dec 31, 2025) will be sufficient to reach key milestones [sec · filed 2026-02-24].
Sources: SEC filings · Generated August 10, 2026 · How we verify sources →
Run Regentis Biomaterials Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Regentis Biomaterials Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
16.1 months
D/E 0.61 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2025Institutional holders
1
Total value held
$70K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 10,412 | $70K |
Short Interest
as of May 22, 2026- % of float
- 0.4%
- Days to cover
- 3.3
- Shares short
- 12,485
- Daily short volume (Jun 2, 2026)
- 56.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGNT short interestFrequently asked questions
What is the AI investment thesis for Regentis Biomaterials Ltd.?
Regentis Biomaterials Ltd. is a development-stage medical device company focused on its Gelrin hydrogel platform and lead product candidate GelrinC, with no product revenue and a history of operating losses.
Who is the CEO of Regentis Biomaterials Ltd.?
Dr. Ehud Geller Ph.D. is the chief executive officer of Regentis Biomaterials Ltd. (RGNT).
Where is Regentis Biomaterials Ltd. headquartered?
Regentis Biomaterials Ltd. (RGNT) is headquartered in Herzliya, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.